NewAmsterdam Pharma N.V. (NAMS) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Novavax (NVAX) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 23.7% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with -93.2% for NVAX. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.52 billion vs $2.09 billion), about 1.2 times the size, while Novavax is growing revenue faster (+64.7% vs -50.6%).
Novavax converts more of its revenue into profit, with a net margin of 39.2% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | NVAX |
|---|---|---|
| Share price | $21.57 | $12.70 |
| Market cap | $2.52B | $2.09B |
| 1-day change | +1.46% | +15.34% |
| YTD return | -39.40% | +63.84% |
| 1-year return | -35.30% | +23.71% |
| 5-year return | +117.16% | -93.20% |
| EPS (TTM) | $-2.16 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | $1.12B |
| Revenue growth (YoY) | -50.61% | +64.69% |
| Net income (latest FY) | $-203.82M | $440.30M |
| Gross margin | — | 93.50% |
| Operating margin | -1002.90% | 40.30% |
| Net margin | -905.74% | 39.19% |
| 52-week high | $42.21 | $13.39 |
| 52-week low | $20.91 | $6.20 |
| Distance from 52-week high | -48.89% | -5.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +130.18% | +10.25% |
| Average volume | 1.36M | 5.21M |
| Shares outstanding | 116.90M | 164.95M |
| Employees | 100 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed NAMS by 59.0 percentage points over the past year.
- Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Novavax grew revenue faster in its latest fiscal year (+64.69% vs -50.61%).
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
NAMS vs NVAX FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Novavax?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.52B compared with $2.09B for Novavax (NVAX).
Which stock has performed better over the past year, NAMS or NVAX?
NVAX returned +23.71% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Novavax in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for NewAmsterdam Pharma N.V. and Biotechnology: Biological Products (No Diagnostic Substances) for Novavax.